Livzon Pharmaceutical's (HKG:1513, SHE:000513) controlling subsidiary, Livzon MABPharm, obtained a drug registration certificate for Lecankitug Injection approved by China's National Medical Products Administration.
The drug was jointly developed by Livzon MABPharm and Beijing Xinkanghe Biomedical Technology, according to a Thursday Hong Kong bourse filing.
The approval is for the indication of the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.